← Leaderboards
Xiaoming He
University Of South Carolina At Columbia
$8,089,332
Attributed
$13,301,009
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2011–24$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,301,009 · 8
By mechanism
R01$13,301,009 · 8
Top collaborators
- Xiongbin Lu10 shared
- Prosper N Boyaka5 shared
- Xi Jiang5 shared
- Jianrong Li5 shared
- Shaik O Rahaman3 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsIn VitroEncapsulatedMortalityPublic HealthAlginatesThree Dimensional Cell CultureStem CellsWomanComplexNovel StrategiesCell SurvivalHydrogelsCessation Of LifeMiniaturizeMicrocapsules Drug Delivery SystemChemotherapyMalignant NeoplasmsBaseResistanceMalignant Breast NeoplasmMammalian CellFuture
Grant awards (32)
Investigate the mechanisms underlying microRNA-146a activity in regulation of foreign body response to biomaterials$703,177
R01 · FY2024 · AI
Cold-responsive gene and drug delivery-potentiated cryoimmunotherapy$429,350
R01 · FY2024 · CA · contact PI
Multiscale hydrogel biomaterials-enabled 3D modeling of cancer drug resistance$399,272
R01 · FY2024 · CA · contact PI
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer$235,233
R01 · FY2024 · CA · contact PI
Investigate the mechanisms underlying microRNA-146a activity in regulation of foreign body response to biomaterials$717,801
R01 · FY2023 · AI
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer$441,858
R01 · FY2023 · CA · contact PI
Multiscale hydrogel biomaterials-enabled 3D modeling of cancer drug resistance$440,347
R01 · FY2023 · CA · contact PI
Investigate the mechanisms underlying microRNA-146a activity in regulation of foreign body response to biomaterials$736,942
R01 · FY2022 · AI
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer$441,579
R01 · FY2022 · CA · contact PI
Nanotechnology for targeted therapy and fundamental understanding of therapeutic resistance in triple negative breast cancer$455,670
R01 · FY2021 · CA · contact PI
A novel lactic acid bacteria-based norovirus vaccine$592,019
R01 · FY2020 · AI
Nanotechnology for targeted therapy and fundamental understanding of therapeutic resistance in triple negative breast cancer$472,539
R01 · FY2020 · CA · contact PI
Nanotechnology enabled targeting of p53 deficiency in human cancer$463,867
R01 · FY2020 · CA · contact PI
Microfluidic encapsulation of ovarian follicles for biomimetic 3D culture andcryopreservation$416,976
R01 · FY2020 · EB · contact PI
Nanotechnology enabled targeting of p53 deficiency in human cancer$42,815
R01 · FY2020 · CA · contact PI
A novel lactic acid bacteria-based norovirus vaccine$597,289
R01 · FY2019 · AI
Microfluidic encapsulation of ovarian follicles for biomimetic 3D culture andcryopreservation$416,976
R01 · FY2019 · EB · contact PI
Nanotechnology enabled targeting of p53 deficiency in human cancer$343,342
R01 · FY2019 · CA · contact PI
A novel lactic acid bacteria-based norovirus vaccine$597,772
R01 · FY2018 · AI
Nanotechnology enabled targeting of p53 deficiency in human cancer$353,962
R01 · FY2018 · CA · contact PI
Microfluidic encapsulation of ovarian follicles for biomimetic 3D culture andcryopreservation$342,000
R01 · FY2018 · EB · contact PI
Microfluidic encapsulation of ovarian follicles for biomimetic 3D culture andcryopreservation$31,746
R01 · FY2018 · EB · contact PI
A novel lactic acid bacteria-based norovirus vaccine$607,519
R01 · FY2017 · AI
Nanotechnology enabled targeting of p53 deficiency in human cancer$359,138
R01 · FY2017 · CA · contact PI
Microfluidic encapsulation of ovarian follicles for biomimetic 3D culture and cryopreservation$348,188
R01 · FY2017 · EB · contact PI
A novel lactic acid bacteria-based norovirus vaccine$618,184
R01 · FY2016 · AI
Nanotechnology enabled targeting of p53 deficiency in human cancer$371,490
R01 · FY2016 · CA · contact PI
Microencapsulation of oocytes for low-CPA (cryoprotectant) vitrification$329,975
R01 · FY2014 · EB · contact PI
Microencapsulation of oocytes for low-CPA (cryoprotectant) vitrification$323,657
R01 · FY2013 · EB · contact PI
Microencapsulation of oocytes for low-CPA (cryoprotectant) vitrification$343,476
R01 · FY2012 · EB · contact PI
Microencapsulation of oocytes for low-CPA (cryoprotectant) vitrification$244,542
R01 · FY2011 · EB · contact PI
Microencapsulation of oocytes for low-CPA (cryoprotectant) vitrification$82,308
R01 · FY2011 · EB · contact PI